SUDA Ltd Annual Update 2015; Advances Pipeline & Begins Deal Negotiations

SUDA LTD has advanced its pipeline of OroMist® oral sprays in 2015 including finalising the design of pivotal trials for two of its lead products and a successful meeting with FDA. The Company has made significant progress towards its business development goals to out-license its products to the pharmaceutical companies across the world.

Discussions with prospective partners span SUDA’s novel sublingual antimalarial spray, ArTiMist™, and its oral sprays for insomnia, migraine, nausea, and erectile dysfunction, as well as the application of SUDA’s OroMist® technology to new compounds. Discussions are at various stages with some companies having completed due diligence and initiated deal negotiations.

The Company’s operations have expanded in 2015 with the addition of new staff as well as the formation of SUDA Europe in London, UK, to widen its business development footprint and provide access to further grant funding and the UK patent box.

SUDA anticipates that 2016 will be an exciting year for the Company with the prospect of securing several commercial deals, creating significant shareholder value.

ABOUT SUDA

SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, WA. The Company is developing low-risk oral sprays using novel formulations of existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums) include ease of use, lower dosage, reduced side effects and faster response time.

SUDA’s product pipeline includes first-in-class oral sprays for insomnia, malaria, migraine, nausea and vomiting, erectile dysfunction and pre-procedural anxiety.